Latest filings (excl ownership)
REVOKED
Registration or securities revoked
20 Oct 23
NT 10-Q
Notice of late quarterly filing
12 Aug 22
10-Q
2022 Q1
Quarterly report
23 May 22
NT 10-Q
Notice of late quarterly filing
16 May 22
10-K
2021 FY
Annual report
15 Apr 22
NT 10-K
Notice of late annual filing
30 Mar 22
8-K
Entry into a Material Definitive Agreement
24 Mar 22
10-Q
2021 Q3
Quarterly report
12 Nov 21
8-K
Regulation FD Disclosure
28 Sep 21
10-Q
2021 Q2
Quarterly report
6 Aug 21
EFFECT
Notice of effectiveness
6 Jul 21
POS AM
Prospectus update (post-effective amendment)
23 Jun 21
10-Q
2021 Q1
Quarterly report
13 May 21
10-K
2020 FY
Annual report
30 Mar 21
8-K
Departure of Directors or Certain Officers
17 Mar 21
D
$1.21M in equity / options / securities to be acquired, sold $1.21M, 1 investor
23 Feb 21
8-K
Entry into a Material Definitive Agreement
23 Feb 21
8-K
Neuropathix, Inc. Acquires Neuroprotective and Anticonvulsant Intellectual Property Estate
21 Dec 20
8-K
Neuropathix, Inc. Signs Binding Letter of Intent to Acquire Anticonvulsant – Neuroprotective Intellectual Property
19 Nov 20
10-Q
2020 Q3
Quarterly report
12 Nov 20
8-K
Kannalife, Inc. Rebrands as Neuropathix, Inc.; Reveals New Name, Ticker Symbol, Updated Logo and Visual Identity
6 Nov 20
EFFECT
Notice of effectiveness
5 Oct 20
CORRESP
Correspondence with SEC
30 Sep 20
UPLOAD
Letter from SEC
29 Sep 20
8-K
Entry into a Material Definitive Agreement
22 Sep 20
S-1
IPO registration
22 Sep 20
10-Q
2020 Q2
Quarterly report
12 Aug 20
8-K
Entry into a Material Definitive Agreement
29 Jun 20
8-K
Entry into a Material Definitive Agreement
11 Jun 20
10-Q
2020 Q1
Quarterly report
14 May 20
8-K
Entry into a Material Definitive Agreement
10 Apr 20
8-K
Changes in Control of Registrant
10 Apr 20
10-K
2019 FY
Annual report
30 Mar 20
8-K
Entry into a Material Definitive Agreement
18 Mar 20
8-K
Regulation FD Disclosure
28 Jan 20
D
$3M in debt / options / securities to be acquired, sold $100K, 1 investor
14 Jan 20
10-Q
2019 Q3
Quarterly report
13 Nov 19
CT ORDER
Confidential treatment order
14 Aug 19
10-Q
2019 Q2
Quarterly report
13 Aug 19
EFFECT
Notice of effectiveness
13 Aug 19
Latest ownership filings
4
DEAN PETKANAS
13 Jun 22
4
DEAN PETKANAS
2 Jun 22
4
DEAN PETKANAS
7 Jan 22
4
DEAN PETKANAS
2 Aug 21
4/A
DEAN PETKANAS
18 Mar 21
4/A
THOMAS EVANGELOS KIKIS
18 Mar 21
4
ROBERT MALASEK
16 Mar 21
4
Timothy Richard Scott
16 Mar 21
4
Blake Schroeder
16 Mar 21
4
Mark Corrao
16 Mar 21
4
THOMAS EVANGELOS KIKIS
16 Mar 21
4
DEAN PETKANAS
16 Mar 21
4
WILLIAM KINNEY
16 Mar 21
4
THOMAS EVANGELOS KIKIS
6 May 20
4
Timothy Richard Scott
6 May 20
4
Blake Schroeder
6 May 20
4
DEAN PETKANAS
6 May 20
4
Timothy Richard Scott
6 May 20
4
ROBERT MALASEK
6 May 20
4
WILLIAM KINNEY
6 May 20
4
Mark Corrao
6 May 20
4
Blake Schroeder
6 May 20
4
DEAN PETKANAS
6 May 20
4
ROBERT MALASEK
6 May 20
4
WILLIAM KINNEY
6 May 20
4
DEAN PETKANAS
3 Dec 19
SC 13D/A
TYG Solutions Corp.
25 Sep 18
3/A
Initial statement of insider ownership (amended)
24 Sep 18
SC 13D
TYG Solutions Corp.
8 Aug 18
4
Change in insider ownership
8 Aug 18
3
Initial statement of insider ownership
8 Aug 18
SC 13D
TYG Solutions Corp.
7 Aug 18
SC 13D
TYG Solutions Corp.
7 Aug 18
SC 13D
TYG Solutions Corp.
7 Aug 18
4
JAMES R ARABIA
7 Aug 18
3
JAMES R ARABIA
7 Aug 18
3
DEAN PETKANAS
7 Aug 18
SC 13D
TYG Solutions Corp.
7 Aug 18
SC 13D
TYG Solutions Corp.
7 Aug 18
3
Mark Corrao
7 Aug 18